


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 403/06, 405/04, A61K 31/505, C07D 401/14 // (C07D 403/06, 239:00, 233:00)	A1	(11) International Publication Number: WO 98/49157 (43) International Publication Date: 5 November 1998 (05.11.98)
(21) International Application Number: PCT/EP98/02357 (22) International Filing Date: 17 April 1998 (17.04.98) (30) Priority Data: 97201259.5 25 April 1997 (25.04.97) EP (34) Countries for which the regional or international application was filed: DE et al. (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): ANGIBAUD, Patrick, René [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). VENET, Marc, Gaston [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). FREYNE, Eddy, Jean, Edgard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). (74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B-2340 Beerse (BE).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: FARNESYLTRANSFERASE INHIBITING QUINAZOLINONES**(57) Abstract**

This invention concerns compounds of formula (I), the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; R¹ and R² each independently are hydrogen, hydroxy, halo, cyano, C₁-alkyl, trihalomethyl, trihalomethoxy, C₂-alkenyl, C₁-alkyloxy, hydroxyC₁-alkyloxy, C₁-alkyloxyC₁-alkyloxy, C₁-alkyloxycarbonyl, aminoC₁-alkyloxy, mono- or di(C₁-alkyl)aminoC₁-alkyloxy, Ar¹, Ar¹C₁-alkyl, Ar¹oxy, Ar¹C₁-alkyloxy; or when on adjacent positions R¹ and R² taken together may form a bivalent radical; R³ and R⁴ each independently are hydrogen, halo, cyano, C₁-alkyl, C₁-alkyloxy, Ar¹oxy, C₁-alkylthio, di(C₁-alkyl)amino, trihalomethyl, trihalomethoxy; R⁵ is hydrogen, halo, cyano, optionally substituted C₁-alkyl, C₁-alkyloxycarbonyl or Ar¹; or a radical of the formula -OR¹⁰, -SR¹⁰, -NR¹¹R¹²; R⁶ is an optionally substituted imidazolyl moiety; R⁷ is hydrogen or C₁-alkyl provided that the dotted line does not represent a bond; R⁸ is hydrogen, C₁-alkyl or Ar²CH₂ or Het¹CH₂; R⁹ is hydrogen, C₁-alkyl, C₁-alkyloxy or halo, or R⁸ and R⁹ taken together may form a bivalent radical; Ar¹ and Ar² are optionally substituted phenyl and Het¹ is optionally substituted pyridinyl; having farnesyltransferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.



(I)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

FARNESYLTRANSFERASE INHIBITING QUINAZOLINONES

5 The present invention is concerned with novel quinazolinone derivatives, the preparation thereof, pharmaceutical compositions comprising said novel compounds and the use of these compounds as a medicine as well as methods of treatment by administering said compounds.

10 Genetic research has led to the identification of a variety of gene families in which mutations can lead to the development of a wide variety of tumors. A particular group of genes, known as *ras*, have been identified in mammals, birds, insects, mollusks, plants, fungi and yeasts. The family of mammalian *ras* genes consists of three major members ("isoforms") : H-*ras*, K-*ras* and N-*ras* genes. These *ras* genes code for highly related proteins generically known as p21^{*ras*}. These p21^{*ras*} proteins comprise a family
15 of proteins that regulate cell growth when bound to the inner surface of the plasma membrane. However, overproduction of p21^{*ras*} proteins, or mutations of said *ras* genes thereby coding for mutant or oncogenic forms of p21^{*ras*} proteins, lead to uncontrolled cell division. In order to regulate cell growth, the *ras* proteins need to be attached to the inner leaflet of the plasma membranes. If mutated or oncogenic forms of
20 p21^{*ras*}, the p21^{*ras*} oncoproteins, become attached to plasma membranes, they provide a signal for the transformation of normal cells to tumor cells and promote their uncontrolled growth. To acquire this transforming potential, the precursor of the p21^{*ras*} oncoprotein must undergo an enzymatically catalyzed farnesylation of the cysteine residue located in a carboxyl-terminal tetrapeptide. Therefore, inhibitors of the
25 enzyme that catalyzes this modification, farnesyl protein transferase, will prevent the membrane attachment of p21^{*ras*} and block the aberrant growth of *ras*-transformed tumors. Hence, it is generally accepted in the art that farnesyl transferase inhibitors can be very useful as anticancer agents for tumors in which *ras* contributes to transformation.

30 Since mutated or oncogenic forms of *ras* are frequently found in many human cancers, most notably in more than 50 % of colon and pancreatic carcinomas (Kohl et al., *Science*, vol 260, 1834 - 1837, 1993), it has been suggested that farnesyl transferase inhibitors can be very useful against these types of cancer.


35 EP-0,371,564 discloses (1*H*-azol-1-ylmethyl) substituted quinoline, quinazoline and quinoxaline derivatives which suppress the plasma elimination of retinoic acids. Some

-2-

of these compounds also have the ability to inhibit the formation of androgens from progestines and/or inhibit the action of the aromatase enzyme complex.

It has been found that the present novel compounds, all having a phenyl substituent on the 4-position of the 2-quinazolinone-moiety bearing a carbon or nitrogen-linked imidazolyl moiety, show farnesyl protein transferase inhibiting activity.

The present invention concerns compounds of formula



the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein

the dotted line represents an optional bond;

15 X is oxygen or sulfur;

R¹ and R² each independently are hydrogen, hydroxy, halo, cyano, C₁-6alkyl, trihalomethyl, trihalomethoxy, C₂-6alkenyl, C₁-6alkyloxy, hydroxyC₁-6alkyloxy, C₁-6alkyloxyC₁-6alkyloxy, C₁-6alkyloxycarbonyl, aminoC₁-6alkyloxy, mono- or di(C₁-6alkyl)aminoC₁-6alkyloxy, Ar¹, Ar¹C₁-6alkyl, Ar¹oxy or Ar¹C₁-6alkyloxy;

20 R³ and R⁴ each independently are hydrogen, halo, cyano, C₁-6alkyl, C₁-6alkyloxy, Ar¹oxy, C₁-6alkylthio, di(C₁-6alkyl)amino, trihalomethyl or trihalomethoxy;

R⁵ is hydrogen, halo, C₁-6alkyl, cyano, haloC₁-6alkyl, hydroxyC₁-6alkyl, cyanoC₁-6alkyl, aminoC₁-6alkyl, C₁-6alkyloxyC₁-6alkyl, C₁-6alkylthioC₁-6alkyl, aminocarbonylC₁-6alkyl, C₁-6alkyloxycarbonylC₁-6alkyl, C₁-6alkylcarbonyl-C₁-6alkyl, C₁-6alkyloxycarbonyl, mono- or di(C₁-6alkyl)aminoC₁-6alkyl, Ar¹, Ar¹C₁-6alkyloxyC₁-6alkyl; or a radical of formula

-O-R¹⁰ (a-1),

-S-R¹⁰ (a-2),

-N-R¹¹R¹² (a-3),

wherein R^{10} is hydrogen, C_{1-6} alkyl, C_{1-6} alkylcarbonyl, Ar^1 , Ar^1C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl C_{1-6} alkyl, or a radical of formula $-Alk-OR^{13}$ or $-Alk-NR^{14}R^{15}$;

R^{11} is hydrogen, C_{1-6} alkyl, Ar^1 or Ar^1C_{1-6} alkyl;

5 R^{12} is hydrogen, C_{1-6} alkyl, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylaminocarbonyl, Ar^1 , Ar^1C_{1-6} alkyl, C_{1-6} alkylcarbonyl- C_{1-6} alkyl, Ar^1 carbonyl, Ar^1C_{1-6} alkylcarbonyl, aminocarbonylcarbonyl, C_{1-6} alkyloxy C_{1-6} alkylcarbonyl, hydroxy, C_{1-6} alkyloxy, aminocarbonyl, di(C_{1-6} alkyl)amino C_{1-6} alkylcarbonyl, amino, C_{1-6} alkylamino, 10 C_{1-6} alkylcarbonylamino, or a radical of formula $-Alk-OR^{13}$ or $-Alk-NR^{14}R^{15}$;



wherein Alk is C_{1-6} alkanediyl;

R^{13} is hydrogen, C_{1-6} alkyl, C_{1-6} alkylcarbonyl, hydroxy C_{1-6} alkyl, Ar^1 or Ar^1C_{1-6} alkyl;

15 R^{14} is hydrogen, C_{1-6} alkyl, Ar^1 or Ar^1C_{1-6} alkyl;

R^{15} is hydrogen, C_{1-6} alkyl, C_{1-6} alkylcarbonyl, Ar^1 or Ar^1C_{1-6} alkyl;

R^6 is a radical of formula



20 wherein R^{16} is hydrogen, halo, Ar^1 , C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-6} alkyloxy C_{1-6} alkyl, C_{1-6} alkyloxy, C_{1-6} alkylthio, amino, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylthio C_{1-6} alkyl, C_{1-6} alkylS(O) C_{1-6} alkyl or C_{1-6} alkylS(O) $_2C_{1-6}$ alkyl;

R^{17} is hydrogen, C_{1-6} alkyl or di(C_{1-4} alkyl)aminosulfonyl;

25 R^7 is hydrogen or C_{1-6} alkyl provided that the dotted line does not represent a bond;

R^8 is hydrogen, C_{1-6} alkyl or Ar^2CH_2 or Het^1CH_2 ;

R^9 is hydrogen, C_{1-6} alkyl, C_{1-6} alkyloxy or halo; or

R^8 and R^9 taken together to form a bivalent radical of formula

30 $-CH=CH-$ (c-1),
 $-CH_2-CH_2-$ (c-2),
 $-CH_2-CH_2-CH_2-$ (c-3),
 $-CH_2-O-$ (c-4), or
 $-CH_2-CH_2-O-$ (c-5);

- Ar¹ is phenyl; or phenyl substituted with 1 or 2 substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trifluoromethyl;
- Ar² is phenyl; or phenyl substituted with 1 or 2 substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trifluoromethyl; and
- 5 Het¹ is pyridinyl; pyridinyl substituted with 1 or 2 substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trifluoromethyl.

As used in the foregoing definitions and hereinafter, halo is generic to fluoro, chloro, bromo and iodo; C₁₋₂alkyl defines methyl or ethyl; C₁₋₄alkyl includes C₁₋₂alkyl and the
10 higher homologues thereof having 3 to 4 carbon atoms such as, e.g. propyl, butyl, 1-methylethyl, 2-methylpropyl and the like; C₁₋₆alkyl includes C₁₋₄alkyl and the higher homologues thereof having 5 to 6 carbon atoms such as, for example, pentyl, 2-methylbutyl, hexyl, 2-methylpentyl and the like; C₂₋₆alkenyl defines straight and branched chain hydrocarbon radicals containing one double bond and having from 2 to 6 carbon atoms
15 such as, for example, ethenyl, 2-propenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, and the like; C₁₋₆alkanediyl defines bivalent straight and branched chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms, such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanedyl, 1,6-hexanediyl and the branched isomers thereof. The term "S(O)" refers to a sulfoxide and
20 "S(O)₂" to a sulfon.

The pharmaceutically acceptable acid addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The compounds of formula (I) which have
25 basic properties can be converted in their pharmaceutically acceptable acid acid addition salts by treating said base form with an appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (*i.e.* butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic,
30 benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-amino-salicylic, pamoic and the like acids.

The term acid addition salts also comprises the hydrates and the solvent addition forms
35 which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

The term stereochemically isomeric forms of compounds of formula (I), as used hereinbefore, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formula (I) may possess. Unless otherwise
5 mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of formula (I) both in pure form or in admixture with each other are
10 intended to be embraced within the scope of the present invention.

Some of the compounds of formula (I) may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included
15 within the scope of the present invention.

In those compounds where the dotted line does not represent a bond, the nitrogen on the 3-position of the quinazolinone moiety allows for an extra bond, *i.e.* radical R⁷. In those compounds where the dotted line represents a bond, said radical R⁷ is absent.
20 Wherever R⁸ and R⁹ are taken together to form a bivalent radical of formula (c-4) or (c-5), the CH₂ moiety in said bivalent radical is preferably connected to the nitrogen atom of the 2-quinazolinone moiety of the compounds of formula (I).

Whenever used hereinafter, the term "compounds of formula (I)" is meant to include
25 also the pharmaceutically acceptable acid addition salts and all stereoisomeric forms.

A group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply :

- a) R¹ and R² are each independently selected from hydrogen, halo, C₁₋₆alkyl,
30 C₁₋₆alkyloxy or trihalomethyl; in particular hydrogen, halo or C₁₋₄alkyl;
- b) R³ and R⁴ are each independently selected from hydrogen, halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trihalomethyl; in particular hydrogen, halo or C₁₋₄alkyl;
- c) R⁵ is hydrogen, hydroxy, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkyloxycarbonylC₁₋₆alkyl, or a radical of formula -NR¹¹R¹² wherein R¹¹ is
35 hydrogen or C₁₋₆alkyl and R¹² is hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxy-C₁₋₆alkylcarbonyl; in particular R⁵ is hydrogen, hydroxy, halo or amino;

- d) R⁶ is a radical of formula (b-1) or (b-2) wherein R¹⁶ is hydrogen or C₁₋₆alkyl and R¹⁷ is C₁₋₆alkyl;
e) R⁷ is hydrogen or C₁₋₆alkyl in case the dotted line does not represent a bond;
f) R⁸ is hydrogen, C₁₋₆alkyl or Het¹CH₂;
5 g) R⁹ is hydrogen.


A particular group of compounds consists of those compounds of formula (I) wherein X is oxygen, R¹ and R² are each independently selected from hydrogen, halo or C₁₋₄alkyl; R³ and R⁴ are each independently selected from hydrogen, halo or C₁₋₄alkyl; R⁵ is
10 hydrogen, hydroxy, halo or a amino; R⁶ is a radical of formula (b-1) or (b-2) wherein R¹⁶ is hydrogen or C₁₋₄alkyl and R¹⁷ is C₁₋₄alkyl; R⁷ is hydrogen or C₁₋₄alkyl in case the dotted line does not represent a bond; R⁸ is hydrogen; C₁₋₄alkyl or Het¹CH₂; and R⁹ is hydrogen.

- 15 Preferred compounds are those compounds of formula (I) wherein X is oxygen, R¹ is 3-chloro, R² is hydrogen, R³ is 4-chloro, R⁴ is hydrogen, R⁵ is hydrogen, C₁₋₂alkyl, halo or amino; R⁶ is a radical of formula (b-1) or (b-2) wherein R¹⁶ is hydrogen and R¹⁷ is C₁₋₂alkyl; and R⁷ is hydrogen or C₁₋₂alkyl in case the dotted line does not represent a bond; R⁸ is hydrogen; C₁₋₂alkyl or Het¹CH₂; and R⁹ is hydrogen.
20


The most preferred compounds of formula (I) are
6-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinazolinone; and
6-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-3,4-
25 dihydro-1,3-dimethyl-2(1*H*)-quinazolinone; the stereoisomeric forms and the pharmaceutically acceptable acid addition salts thereof.

The compounds of formula (I) wherein R⁶ is a radical of formula (b-1), represented by compounds of formula (I-a), can generally be prepared by *N*-alkylating an intermediate
30 of formula (III), with an intermediate of formula (II), wherein W is an appropriate leaving group such as, for example, chloro, bromo, methanesulfonyloxy or benzenesulfonyloxy. The reaction can be performed in a reaction-inert solvent such as, for example, acetonitrile, and optionally in the presence of a suitable base such as, for example, sodium carbonate, potassium carbonate or triethylamine. Stirring may enhance
35 the rate of the reaction. The reaction may conveniently be carried out at a temperature ranging between room temperature and reflux temperature.

-7-




Also, compounds of formula (I-a) can be prepared by reacting an intermediate of formula (IV) with an intermediate of formula (V), wherein Y is carbon or sulfur, such as, for example, a 1,1'-carbonyldiimidazole.



Said reaction may conveniently be conducted in a reaction-inert solvent, such as, e.g. tetrahydrofuran, optionally in the presence of a base, such as sodium hydride, and at a temperature ranging between room temperature and the reflux temperature of the reaction mixture.

The compounds of formula (I) wherein R⁶ represents a radical of formula (b-2), R⁵ is hydroxy and R¹⁷ is C₁₋₆alkyl, said compounds being referred to as compounds of formula (I-b-1) may be prepared by reacting an intermediate ketone of formula (VI) with an intermediate of formula (III-1). Said reaction requires the presence of a suitable strong base, such as, for example, butyl lithium in an appropriate solvent, such as, for example, tetrahydrofuran, and the presence of an appropriate silanederivative, such as, for example, triethylchlorosilane. During the work-up procedure an intermediate silane derivative is hydrolyzed. Other procedures with protective groups analogous to silanederivatives can also be applied.


-8-



Also, the compounds of formula (I), wherein R^6 is a radical of formula (b-2), R^5 is hydroxy and R^{17} is hydrogen, said compounds being referred to as compounds of formula (I-b-2) may be prepared by reacting an intermediate ketone of formula (VI) with a intermediate of formula (III-2), wherein PG is a protective group such as, for example, a sulfonyl group, e.g. a dimethylamino sulfonyl group, which can be removed after the addition reaction. Said reaction is conducted analogously as for the preparation of compounds of formula (I-b-1), followed by removal of the protecting group PG, yielding compounds of formula (I-b-2).


Compounds of formula (I-c), defined as compounds of formula (I) wherein R^7 is hydrogen and the dotted line does not represent a bond, can be converted into compounds of formula (I-d), defined as compounds of formula (I) wherein the dotted line represents a bond, by art-known oxidation procedures such as, e.g. oxidation with MnO_2 in a reaction-inert solvent, e.g. dichloromethane.

-9-




Conversely, compounds of formula (I-d) can be converted to compounds of formula (I-c) using art-known reduction procedures such as, e.g. treatment with sodiumborohydride in a suitable solvent, e.g. methanol.

Also, compounds of formula (I-c) can be converted to compounds of formula (I-c-1) by treating compounds (I-c) with a reagent of formula R^7-W^1 , wherein W^1 is an appropriate leaving group such as, for example, chloro, bromo, methanesulfonyloxy or benzenesulfonyloxy, using the above-described *N*-alkylation procedure.




The compounds of formula (I-b) can be converted to compounds of formula (I-e), defined as a compound of formula (I) wherein R^6 is a radical of formula (b-2) and R^5 is hydrogen, by submitting the compounds of formula (I-b) to appropriate reducing conditions, such as, e.g. stirring in acetic acid in the presence of formamide.

-10-




- Further, compounds of formula (I-b) can be converted to compounds of formula (I-f) wherein R^5 is halo, by reacting the compounds of formula (I-b) with a suitable halogenating agent, such as, e.g. thionyl chloride or phosphorus tribromide.
- 5 Successively, the compounds of formula (I-f) can be treated with a reagent of formula $H-NR^{11}R^{12}$ in a reaction-inert solvent, thereby yielding compounds of formula (I-g).




10

A compound of formula (I-i), defined as a compound of formula (I) wherein X is sulfur, may be prepared by reacting the corresponding compound of formula (I-h), defined as a compound of formula (I) wherein X is oxygen, with a reagent like phosphorus pentasulfide or Lawesson's reagent in a suitable solvent such as, for example, pyridine.


15




An intermediate of formula (II-a), being an intermediate of formula (II) wherein X is oxygen and R⁷ and R⁸ are hydrogen, can be prepared starting from an intermediate of formula (VII). Said intermediate (VII), wherein n is 2 or 3, is conveniently prepared by protecting the corresponding art-known ketone as a ketal. An intermediate of formula (VII) is reacted with an intermediate of formula (VIII) in the presence of a base such as sodium hydroxide, in an appropriate solvent, e.g. methanol. The thus obtained intermediate of formula (IX) undergoes ring opening of the isoxazole moiety by hydrogenation of intermediate (IX) in the presence of a suitable catalyst such as, e.g. Raney Nickel. Subsequent acylation with a reactive carboxylic acid derivative, e.g. trichloroacetyl chloride or trifluoroacetyl chloride, yields an intermediate of formula (X), which undergoes ring closure in the presence of an ammonium salt, e.g. ammonium acetate, and an appropriate base such as, e.g. hexamethylphosphorous triamide (HMPT). Intermediates of formula (X) are submitted to acidic conditions and subsequently treated with art-known reducing agents such as, e.g. sodium borohydride, yielding intermediates of formula (XII). The hydroxy group of intermediates of formula (XII) is converted to a leaving group W by treating intermediates (XII) with a suitable reagent such as, e.g. methanesulfonyloxy chloride, or a halogenating reagent such as, e.g. POCl₃ or SOCl₂, yielding intermediates of formula (II-a).



-12-




- Intermediates of formula (II-b), defined as intermediates of formula (II) wherein X is O and R⁷ is hydrogen, can be prepared by reacting intermediates of formula (XI) with R⁸-W¹, wherein W¹ is a suitable leaving group such as, e.g. chloro, bromo, methanesulfonyloxy or benzenesulfonyloxy; using the above-described *N*-alkylation procedure. Subsequent reduction with e.g. sodiumborohydride in a suitable solvent, e.g. methanol, and hydrolysis under acidic conditions, yields intermediates of formula (XIV). Conversion of the hydroxy group of intermediates (XIV) into leaving group W, e.g. by treatment with methanesulfonyloxy chloride or a halogenating reagent such as, e.g. SOCl₂, POCl₃, gives intermediates of formula (II-b).




- Intermediates of formula (VI-a), defined as intermediates of formula (VI) wherein X is O and the dotted line does not represent a bond, can be prepared by submitting intermediates of formula (XIII) to art-known reduction procedures, such as, e.g. treatment with sodium borohydride in a reaction-inert solvent e.g. methanol, thereby

yielding intermediates of formula (XV). Intermediates (XV) are *N*-alkylated with R^7-W^1 , wherein W^1 is a leaving group as above-described, and subsequently hydrolysed under acidic conditions to intermediates of formula (VI-a).



Also, intermediates of formula (VI-b), defined as intermediates of formula (VI) wherein X is O and the dotted line represents a bond, can be prepared by hydrolysis of the intermediate of formula (IX) with an acid, such as for example, $TiCl_3$, in the presence of water. Subsequent acylation with a reactive carboxylic acid derivative, such as, e.g. trichloroacetyl chloride, yields an intermediate of formula (XVII), which undergoes ring closure in the presence of an ammonium salt, e.g. ammonium acetate, and an appropriate base such as, e.g. hexamethylphosphorous triamide (HMPT), thereby yielding an intermediate of formula (VI-b).



The compounds of formula (I) and some of the intermediates have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration.

- 5 The compounds of formula (I) as prepared in the hereinabove described processes are generally racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for
10 example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting
15 materials, provided that the reaction occurs stereospecifically. Specific stereoisomers can be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

- This invention provides a method for inhibiting the abnormal growth of cells, including
20 transformed cells, by administering an effective amount of a compound of the invention. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g. loss of contact inhibition). This includes the abnormal growth of : (1) tumor cells (tumors) expressing an activated *ras* oncogene; (2) tumor cells in which the *ras* protein is activated as a result of oncogenic mutation of another
25 gene; (3) benign and malignant cells of other proliferative diseases in which aberrant *ras* activation occurs. Furthermore, it has been suggested in literature that *ras* oncogenes not only contribute to the growth of of tumors *in vivo* by a direct effect on tumor cell growth but also indirectly, *i.e.* by facilitating tumor-induced angiogenesis (Rak. J. et al, *Cancer Research*, 55, 4575-4580, 1995). Hence, pharmacologically
30 targetting mutant *ras* oncogenes could conceivably suppress solid tumor growth *in vivo*, in part, by inhibiting tumor-induced angiogenesis.

- This invention also provides a method for inhibiting tumor growth by administering an effective amount of a compound of the present invention, to a subject, e.g. a mammal
35 (and more particularly a human) in need of such treatment. In particular, this invention provides a method for inhibiting the growth of tumors expressing an activated *ras*

oncogene by the administration of an effective amount of the compounds of the present invention. Examples of tumors which may be inhibited, but are not limited to, lung cancer (e.g. adenocarcinoma), pancreatic cancers (e.g. pancreatic carcinoma such as, for example exocrine pancreatic carcinoma), colon cancers (e.g. colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), hematopoietic tumors of lymphoid lineage (e.g. acute lymphocytic leukemia, B-cell lymphoma, Burkitt's lymphoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), tumors of mesenchymal origin (e.g. fibrosarcomas and rhabdomyosarcomas), melanomas, teratocarcinomas, neuroblastomas, gliomas, benign tumor of the skin (e.g. keratoacanthomas), breast carcinoma, kidney carcinoma, ovary carcinoma, bladder carcinoma and epidermal carcinoma.

This invention may also provide a method for inhibiting proliferative diseases, both benign and malignant, wherein *ras* proteins are aberrantly activated as a result of oncogenic mutation in genes, i.e. the *ras* gene itself is not activated by mutation to an oncogenic form, with said inhibition being accomplished by the administration of an effective amount of the compounds described herein, to a subject in need of such a treatment. For example, the benign proliferative disorder neurofibromatosis, or tumors in which *ras* is activated due to mutation or overexpression of tyrosine kinase oncogenes may be inhibited by the compounds of this invention.

Hence, the present invention discloses the compounds of formula (I) for use as a medicine as well as the use of these compounds of formula (I) for the manufacture of a medicament for treating one or more of the above mentioned conditions.

In view of their useful pharmacological properties, the subject compounds may be formulated into various pharmaceutical forms for administration purposes.

To prepare the pharmaceutical compositions of this invention, an effective amount of a particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water,

glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules
5 represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, to aid solubility for example, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose
10 solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which
15 additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for
20 ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including
25 scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

Those skilled in the art could easily determine the effective amount from the test
30 results presented hereinafter. In general it is contemplated that an effective amount would be from 0.01 mg/kg to 100 mg/kg body weight, and in particular from 0.05 mg/kg to 10 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.05 to
35 500 mg, and in particular 0.1 mg to 200 mg of active ingredient per unit dosage form.

The following examples are provided for purposes of illustration.

Experimental part

A. Preparation of the intermediates.

- 5 Hereinafter "THF" means tetrahydrofuran, "DIPE" means diisopropylether, "DCM" means dichloromethane, "DMF" means *N,N*-dimethylformamide and "ACN" means acetonitrile.

Of some compounds of formula (I) the absolute stereochemical configuration was not experimentally determined. In those cases the stereochemically isomeric form which
10 was first isolated is designated as "A" and the second as "B", without further reference to the actual stereochemical configuration.

Example A.1

- a) A mixture of (4-chlorophenyl)(4-nitrophenyl)methanone (0.0382 mol),
15 1,2-ethanediol (0.0764 mol) and 4-methylbenzenesulfonic acid monohydrate 96% (0.19 mol) in methylbenzene (150 ml) was stirred and refluxed in a Dean Stark apparatus for 24 hours. The mixture was washed with K₂CO₃ (10%) and then with water. The organic layer was dried, filtered off and evaporated. The product was used without further purification, yielding 11.42g (98%) of 2-(4-chlorophenyl)-2-(4-nitro-
20 phenyl)-1,3-dioxolane (interm. 1).
b) Sodium hydroxide (0.818 mol) and then 3-chlorobenzenacetonitrile (0.294 mol) were added to a solution of intermediate (1) (0.164 mol) in methanol (200 ml) and the mixture was stirred at room temperature overnight. The mixture was quenched with water and extracted with DCM. The organic layer was dried, filtered off and
25 evaporated till dryness. The residue was recrystallized from DIPE, yielding 47.3 g (70%) of 3-(3-chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-2,1-benzisoxazole (interm. 2).
c) Intermediate (2) (0.0381 mol) in methanol (200 ml) was hydrogenated with Raney nickel (15 g) as a catalyst at room temperature over a 5 hour period under a 3×10^5 Pa
30 (3 bar) pressure in a Parr apparatus. After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated till dryness. The product was used without further purification, yielding 15.7 g of [2-amino-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-phenyl](3-chlorophenyl)methanone (interm. 3).
d) A mixture of intermediate (3) (0.098 mol) in DCM (400 ml) was stirred at 5-10°C.
35 Trichloroacetyl chloride (0.12 mol) was added dropwise, over a 15-minutes period, at a temperature between 5-10°C. Triethylamine (0.12 mol) was added dropwise, over a

- 20-minutes period, at 5-10°C. The reaction mixture was stirred for one hour at 5-10°C. Water (250 ml) was added and stirring was continued for 5 minutes. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent : DCM). The desired fractions were collected and the solvent was evaporated. The residue was stirred in ACN, filtered off and dried, yielding 46.5 g (85%) of trichloro-*N*-[2-(3-chlorophenyl)-4-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]phenyl]acetamide (interm. 4).
- 5 e) A mixture of intermediate (4) (0.078 mol) and ammonium acetate (0.156 mol) in hexamethylphosphorous triamide (HMPT) (300 ml) was stirred for 3 hours at 100°C. 10 The reaction mixture was cooled, poured out into ice water (1500 ml) and precipitation resulted. The precipitate was filtered off, and washed with water. The product was dissolved in DCM. The organic layer was isolated, dried, filtered and the solvent evaporated. The residue was purified three times over silica gel on a glass filter (eluent : CH₂Cl₂/CH₃OH 97/3, then 95/5). The desired fractions were collected and the solvent 15 was evaporated. The residue was stirred in refluxing isopropanol (200 ml). The mixture was cooled and the resulting precipitate was filtered off, washed with DIPE, and dried, yielding 26 g (76%) of 4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-2(1*H*)-quinazolinone (interm. 5, mp. 219.5°C).
- 20 f) A mixture of intermediate (5) (0.052 mol) in hydrochloric acid, 3N (250 ml) and methanol (250 ml) was stirred and refluxed for 2 hours. The reaction mixture was cooled. Water (250 ml) was added and the resulting precipitate was filtered off, washed with water, isopropanol and DIPE, then dried, yielding 19.4 g (94.4%) of 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-2(1*H*)-quinazolinone (interm. 6; mp. 256.4°C).
- 25 g) A mixture of intermediate (6) (0.005 mol) in methanol (50 ml) was stirred and cooled on an ice-bath (5-10°C). Sodium borohydride (0.007 mol) was added portionwise over a 15-minutes period (first, dissolution resulted; after 15 minutes precipitation started). The mixture was stirred for 1 hour at room temperature. The mixture was acidified with 1 N HCl. The precipitate was filtered off, washed with DIPE, then dried, yielding 1.6 g (80%) of (±)-4-(3-chlorophenyl)-6-[(4-chloro- 30 phenyl)hydroxymethyl]-3, 4-dihydro-2(1*H*)-quinazolinone (interm. 7; mp. 231.4°C).
- h) A mixture of intermediate (7) (0.013 mol) in DCM (60 ml) was stirred at room temperature. Thionyl chloride (0.065 mol) was added dropwise over a 15-minutes period. The reaction mixture was stirred for 3 hours at room temperature. Dissolution resulted. The solvent was evaporated. Toluene was added and azeotroped on the 35 rotary evaporator, yielding 5.4 g of (±)-6-[chloro(4-chlorophenyl)methyl]-4-(3-chlorophenyl)-3,4-dihydro-2(1*H*)-quinazolinone (interm. 8).

Example A.2

- 5 a) A mixture of intermediate (5) (0.0455 mol) in DMF (500 ml) was stirred at room temperature, under N₂ flow. A dispersion of sodium hydride (50%) in mineral oil (0.0455 mol) was added portionwise. The reaction mixture was stirred until gas evolution stopped. Iodomethane (0.0455 mol) was added dropwise and the resulting reaction mixture was stirred for 14 hours at room temperature. The solvent was evaporated. Toluene was added and azeotroped on the rotary evaporator. The crude oil was stirred in DCM (300 ml), washed with water (2 x 250 ml), dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : DCM). The desired fractions were collected and the solvent was evaporated, yielding 16.7 g (80%) of 4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-1-methyl-2(1*H*)-quinazolinone (interm. 9).
- 10 b) A mixture of intermediate (9) (0.037 mol) in methanol (300 ml) was stirred at room temperature. Hydrochloric acid (0.75 mol) was added dropwise and the resulting reaction mixture was stirred and refluxed for one hour, then cooled to room temperature and extracted with DCM (2 x 250 ml). The separated organic layer was dried, filtered and the solvent evaporated. The residue was triturated in DIPE. The precipitate was filtered off, washed with DIPE (100 ml) and dried (vacuum; 60°C; 14 hours), yielding 12.6 g (83%) of 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinazolinone (interm. 10).
- 15 20

Example A.3

- 25 a) A suspension of intermediate (10) (0.031 mol) in methanol (150 ml) was stirred at room temperature. Sodium borohydride (0.062 mol) was added portionwise (maximal temperature rise of 5°C). The reaction mixture was stirred for 2 hours at room temperature. The precipitate was filtered off, washed with water (50 ml), isopropanol (100 ml) and DIPE (100 ml), then dried (vacuum; 50°C), yielding 11.5 g (90%) of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxymethyl]-3,4-dihydro-1-methyl-2(1*H*)-quinazolinone (interm. 11)
- 30 b) DCM (0.0556 mol) was added dropwise to a mixture of intermediate (11) (0.028 mol) in DCM (100 ml). The reaction mixture was stirred and refluxed for 2 hours. The solvent was evaporated. Toluene was added and azeotroped on the rotary evaporator, yielding 12.09 g of (±)-6-[chloro(4-chlorophenyl)methyl]-4-(3-chlorophenyl)-3,4-dihydro-1-methyl-2(1*H*)-quinazolinone (interm. 12).
- 35

Example A.4

- 5 a) A solution of intermediate (9) (0.0122 mol) in methanol (50 ml) was cooled to 5°C. Sodium borohydride (0.0122 mol) was added portionwise and the mixture was allowed to stand at 5°C for 30 minutes. The mixture was poured out on ice-water. The precipitate was filtered off, washed with water and dried, yielding 5.4 g (98%) of (±)-4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-3,4-dihydro-1-methyl-2(1*H*)-quinazolinone (interm. 13).
- 10 b) Intermediate (13) (0.0107 mol) was dissolved in DMF (50 ml) at 0°C under N₂ flow. A dispersion of sodium hydride (80%) in mineral oil (0.013 mol) was added and the mixture was allowed to stand at 0°C for 30 minutes. Iodomethane (0.0215 mol) was added dropwise and the mixture was allowed to stand at 0°C for 1 hour. The mixture was poured out on ice-water. The precipitate was filtered off, washed with water and taken up in DCM. The organic layer was dried, filtered and the solvent was evaporated, yielding 6.2g of (±)-4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-3,4-dihydro-1,3-dimethyl-2(1*H*)-quinazolinone (interm. 14).
- 15 c) A mixture of intermediate (14) (0.0259 mol) in acetic acid (75 ml), water (20 ml) and THF (10 ml) was stirred and refluxed overnight, and the solvent was evaporated. The residue was taken up in DCM and washed with K₂CO₃ (10%). The organic layer was decanted, dried, filtered, and the solvent was evaporated, yielding 11 g (100%) of product. A sample was crystallized from 2-propanone/DIPE. The precipitate was filtered off and dried, yielding 1.5g of (±)-6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-3,4-dihydro-1,3-dimethyl-2(1*H*)-quinazolinone (interm. 15).
- 20

Example A.5

- 25 a) A mixture of intermediate (5) (0.0175 mol) in DMF (80 ml) was cooled on an ice bath under nitrogen flow. Sodium hydride (80% in oil, 0.0228 mol) was added portionwise and the mixture was stirred at a low temperature for 30 minutes, then at room temperature for 1 hour. The mixture was cooled to 5°C and chloromethyl ethyl ether (0.0228 mol) was added. The mixture was stirred at a low temperature for 30 minutes and then hydrolized. The precipitate was filtered off, washed with water, taken up in DCM, dried, filtered, and the solvent was evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 99/1/0.1), yielding 2.9 g (33.3%) of 4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-1-(ethoxymethyl)-2(1*H*)-quinazolinone (interm. 16).
- 30 b) A mixture of intermediate (16) (0.0058 mol) in methanol (50 ml) was cooled on an ice bath. Sodium borohydride (0.0058 mol) was added portionwise. The mixture was
- 35

stirred at a low temperature for 30 minutes, then poured out into ice water and extracted with DCM. The organic layer was separated, dried, filtered, and the solvent was evaporated till dryness, yielding 2.9 g (100%) of (\pm)-4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-1-(ethoxymethyl)-3,4-dihydro-2(1H)-quinazolinone (interm. 17).

5 c) A mixture of intermediate (17) (0.0058 mol) in DMF (30 ml) was cooled on an ice bath under nitrogen flow. Sodium hydride (80% in oil, 0.007 mol) was added and the mixture was stirred at a low temperature for 30 minutes. Methyl iodide (0.007 mol) was added dropwise. The mixture was stirred at a low temperature for 1 hour, then allowed
10 to warm to room temperature, hydrolyzed and water was added. The precipitate was filtered off, washed with water, taken up in DCM, dried, filtered, and the solvent was evaporated till dryness, yielding 3 g (100%) of (\pm)-4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-1-(ethoxymethyl)-3,4-dihydro-3-methyl-2(1H)-quinazolinone (interm. 18).

15 d) A mixture of intermediate (18) (0.0058 mol) in HCl (30 ml) and THF (30 ml) was stirred and refluxed overnight, cooled by adding ice, basified with $\text{NH}_3(\text{aq.})$ and extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated till dryness. The residue was taken up in 2-propanone and DIPE. The precipitate was filtered off, washed and dried, yielding 2.2 g (91.6%) of (\pm)-6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-3,4-dihydro-3-methyl-2(1H)-quinazolinone (interm.
20 19).

e) Sodium borohydride (0.0053 mol) was added to a mixture of intermediate (19) (0.0053 mol) in methanol (20 ml) and THF (20 ml), previously cooled on an ice bath (5°C). The mixture was stirred at 5°C for 30 minutes, poured out into ice water and
25 extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated till dryness, yielding 2.2 g (100%) of (\pm)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxymethyl]-3, 4-dihydro-3-methyl-2(1H)-quinazolinone (interm. 20).

f) Thionyl chloride (10 ml) was added dropwise to a mixture of intermediate (20) (0.005 mol) in DCM (50 ml), previously cooled on an ice bath (5°C). The mixture was stirred
30 at room temperature for 1 night. The solvent was evaporated till dryness. The product was used without further purification, yielding quantitatively (\pm)-6-[chloro(4-chlorophenyl)methyl]-4-(3-chlorophenyl)-3,4-dihydro-3-methyl-2(1H)-quinazolinone (interm. 21).

B. Preparation of the final products.

Example B.1

A mixture of intermediate (8) (0.013 mol), imidazole (0.039 mol) and potassium carbonate (0.04 mol) in ACN (75 ml) was stirred and refluxed for 3 hours. The solvent was evaporated. The residue was stirred in water and this mixture was extracted with DCM. The separated organic layer was dried, filtered and the solvent evaporated. The residue was purified over silica gel on a glass filter (eluent : CH₂Cl₂/CH₃OH 95/5). The desired fractions were collected and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/(CH₃OH/NH₃) 95/2.5/2.5). The pure fractions were collected and the solvent was evaporated. The residue was stirred in diethyl ether (50 ml), filtered off and dried, yielding 2.6 g (44.5%) of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)-1*H*-imidazol-1-ylmethyl]-3,4-dihydro-2(1*H*)-quinazolinone (comp. 8); mp. 177.1°C.

Example B.2

A mixture of 1-methylimidazole (0.073 mol) in THF (110 ml) was cooled to -70°C under N₂ flow. A solution of *n*-butyllithium in hexane (1.6M) (45.6 ml) was added dropwise. The mixture was stirred at -70°C for 30 minutes. Chlorotriethylsilane (0.073 mol) was added. The mixture was allowed to warm slowly to room temperature and then cooled to -70°C. A solution of *n*-butyllithium in hexane (1.6M) (45.6 ml) was added dropwise. The mixture was stirred at -70°C for 1 hour, then brought to -15°C and cooled to -70°C. A mixture of intermediate (10) (0.061 mol) in THF (100 ml) was added. The mixture was stirred at -70°C for 30 minutes, then brought to 0°C, hydrolyzed, extracted with ethyl acetate and decanted. The organic layer was dried, filtered and the solvent was evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 93/7/0.5), yielding 9.5 g of product. This product was recrystallized from 2-propanone/ACN. The precipitate was filtered off, washed with diethyl ether and dried, yielding 2 g of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-1-methyl-2(1*H*)-quinazolinone monohydrate (comp. 4).

Example B.3

A mixture of compound (8) (0.0045 mol) and manganese(IV) oxide (0.05 mol) in DCM (50 ml) was stirred for 18 hours at room temperature. The mixture was filtered over dicalite. The dicalite was washed with CH₂Cl₂/CH₃OH 90/10. The filtrate was evaporated. The residue was purified over silica gel on a glass filter (eluent:

CH₂Cl₂/CH₃OH 95/5). The desired fractions were collected and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 95/5) and recrystallized from ACN (25 ml). The precipitate was filtered off, washed with DIPE, and dried, yielding 1 g (50%) of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)-1*H*-imidazol-1-ylmethyl]-2(1*H*)-quinazolinone (comp. 1; mp. 255.1°C).

Example B.4

Sodium borohydride (0.003 mol) was added portionwise at 5°C to a mixture of compound (4) (0.003 mol) in methanol (30 ml). The mixture was stirred at 5°C for 30 minutes, then hydrolyzed, extracted with DCM and decanted. The organic layer was dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried, yielding 1 g of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl)-1*H*-imidazol-5-yl)methyl]-3,4-dihydro-1-methyl-2(1*H*)-quinazolinone (comp. 13).

Example B.5

A dispersion of sodium hydride in mineral oil (60%)(0.0047 mol) was added portionwise to a mixture of compound (9) (0.0043 mol) in DMF (40 ml) under N₂ flow. The mixture was stirred for 30 minutes at room temperature. A solution of iodomethane (0.0047 mol) in DMF (10 ml) was added dropwise and the resulting reaction mixture was stirred overnight at room temperature. The reaction mixture was poured out into water (200 ml) and this mixture was extracted with toluene (3 x 100 ml). The separated organic layer was dried, filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent : ethyl acetate/CH₃OH/(CH₃OH/ NH₃) 90/5/5). The pure fractions were collected and the solvent was evaporated. This fraction was repurified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 100/0, upgrading over 20 minutes to 90/10; 125 ml/min). The pure fractions were collected and the solvent was evaporated, yielding 0.370g (18%) of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)-1*H*-imidazol-1-ylmethyl]-3,4-dihydro-1,3-dimethyl-2(1*H*)-quinazolinone (comp. 10).

Example B.6

A dispersion of sodium hydride in mineral oil (60%) (0.01122 mol) was added portionwise to a mixture of compound (1) (0.0051 mol) in DMF (25 ml) under N₂ flow. The mixture was stirred for 30 minutes at room temperature. A solution of
5 4-(chloromethyl)pyridine hydrochloride (0.00561 mol) in DMF (5 ml) was added dropwise and the resulting reaction mixture was stirred over the weekend at room temperature. The reaction mixture was poured out into water and this mixture was extracted with toluene. The separated organic layer was dried, filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent
10 : CH₂Cl₂/CH₃OH/(CH₃OH/NH₃) 90/5/5). The desired fractions were collected and the solvent was evaporated. This fraction was repurified by high-performance liquid chromatography over Kromasil RP-18 (100 Å, 10 µm, 5 cm DAC; eluent: (0.5% NH₄OAc in H₂O)/CH₃OH/CH₃CN 47/25/28 v/v). The pure fractions were collected and the organic solvent was evaporated. The aqueous residue was extracted with DCM.
15 The separated organic layer was dried, filtered, and the solvent evaporated, yielding 0.900 g (32.8%) of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)-1*H*-imidazol-1-ylmethyl]-1-(4-pyridinylmethyl)-2(1*H*)-quinazolinone (comp. 3; mp. 61.4°C).

Example B.7

20 A mixture of compound (4) (0.0069 mol) in formamide (34 ml) and acetic acid (68 ml) was stirred at 160°C for 24 hours, then poured out into ice water and alkalisied with a concentrated NH₃ (aq.) solution. The precipitate was filtered off, washed with water and taken up in DCM. The organic layer was separated, dried, filtered and the solvent was evaporated till dryness. The residue was purified by column chromatography over
25 silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.2). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from 2-propanone/DIPE. The precipitate was filtered off and dried, yielding 0.85 g of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-3,4-dihydro-1-methyl-2(1*H*)-
30 quinazolinone (comp. 14).

Example B.8

Compound (4) (0.01 mol) was added at a low temperature to thionyl chloride (50 ml). The mixture was stirred at 40°C for 2 hours. The solvent was evaporated till dryness. The product was used without further purification, yielding 5.46 g of (±)-6-[chloro(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-
35 quinazolinone monohydrochloride (comp. 6).

Example B.9

Ammonium hydroxide (50 ml) was cooled to 5°C. A solution of compound (6) (0.01 mol) in THF (50 ml) was added. The mixture was stirred at room temperature for 2 hours, then at 60°C for 30 minutes and cooled. Ethyl acetate was added. The mixture was decanted. The organic layer was dried, filtered and the solvent was evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent : toluene/isopropanol/NH₄OH 75/25/2). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from DCM and diethyl ether. The precipitate was filtered off and dried, yielding 1.1 g of (±)-6-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinazolinone (comp. 7).


Example B.10


- 15 a) A mixture of interm. (21) (0.0146 mol), 2-phenylimidazole (0.0219 mol) and potassium carbonate (0.0438 mol) in ACN (80 ml) was stirred and refluxed for 4 hours. The solvent was evaporated till dryness. The residue was taken up in DCM and water. The organic layer was separated, dried, filtered and the solvent was evaporated till dryness. The product was used without further purification, yielding a mixture of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)(2-phenyl-1*H*-imidazol-1-yl)methyl]-2-methoxyquinazoline (interm. 22) and (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)(2-phenyl-1*H*-imidazol-4-yl)methyl]-2-methoxyquinazoline (interm. 23).
- 20 b) A mixture of intermediates (22) and (23) (0.0146 mol) in HCl (3 N, 100 ml) and THF (100 ml) was stirred and refluxed for 3 hours, then poured out into ice water and extracted with ethyl acetate. The organic layer was separated, dried, filtered and the solvent was evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 95/5/0.5). Two pure fractions were collected and their solvents were evaporated. The first fraction was crystallized from ACN, 2-propanone and DIPE, yielding 1.2 g (15.8%) of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)(2-phenyl-1*H*-imidazol-1-yl)methyl]-2(1*H*)-quinazolinone (comp. 19, mp. 170°C). The second fraction was dissolved in 2-propanone and DIPE and converted into the ethanedioic acid salt (1:1), yielding 0.8 g (8.7%) of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)(2-phenyl-1*H*-imidazol-4-yl)methyl]-2(1*H*)-quinazolinone ethanedioate(1:1).monohydrate (comp. 20, mp. 197°C).
- 35

Tables F-1 to F-4 list the compounds that were prepared according to one of the above Examples.


Table F-1

5



Co. No.	Ex. No.	R ¹	R ³	R ⁵	R ⁸	R ¹⁶	Physical data
1	B.3	3-Cl	4-Cl	H	H	H	mp. 255.1°C
2	B.3	3-Cl	4-Cl	H	CH ₃ -	H	mp. 123.3°C
3	B.6	3-Cl	4-Cl	H		H	mp. 61.4°C
19	B.10	3-Cl	4-Cl	H	H	2-phenyl	mp. 170°C


10 Table F-2 :



Co. No.	Ex. No.	R ¹	R ³	R ⁵	R ⁸	Physical data
4	B.2	3-Cl	4-Cl	OH	CH ₃	.H ₂ O (1:1)
5	B.3	3-Cl	4-Cl	H	CH ₃	.ethanedioate (1:1).H ₂ O (1:2)
6	B.8	3-Cl	4-Cl	Cl	CH ₃	.HCl (1:1)
7	B.9	3-Cl	4-Cl	NH ₂	CH ₃	

-27-


Table F-3 :



Co. No.	Ex. No.	R ¹	R ³	R ⁵	R ⁷	R ⁸	R ¹⁶	Physical data
8	B.1	3-Cl	4-Cl	H	H	H	H	mp. 177.1°C
9	B.1	3-Cl	4-Cl	H	H	CH ₃	H	mp. 111.5°C
10	B.5	3-Cl	4-Cl	H	CH ₃	CH ₃	H	-
11	B.5	3-Cl	4-Cl	H	CH ₂ CH ₃	CH ₃	H	mp. 115.8°C
18	B.1	3-Cl	4-Cl	H	CH ₃	H	2-phenyl	mp. 236°C

5

Table F-4 :



Co. No.	Ex. No.	R ¹	R ³	R ⁵	R ⁷	R ⁸	Physical data
12	B.2	3-Cl	4-Cl	OH	CH ₃	CH ₃	-
13	B.4	3-Cl	4-Cl	OH	H	CH ₃	-
14	B.7	3-Cl	4-Cl	H	H	CH ₃	-
15	B.7	3-Cl	4-Cl	H	CH ₃	CH ₃	-
16	B.8	3-Cl	4-Cl	Cl	CH ₃	CH ₃	.HCl (1:1)
17	B.9	3-Cl	4-Cl	NH ₂	CH ₃	CH ₃	(A)

10

C. Pharmacological example.Example C.1 : "Ras-Transformed Cell Phenotype Reversion Assay".

Insertion of activated oncogenes such as the mutant *ras* gene into mouse NIH 3T3 cells converts the cells to a transformed phenotype. The cells become tumorigenic, display anchorage independent growth in semi-solid medium and lose contact inhibition. Loss of contact inhibition produces cell cultures which no longer form uniform monolayers. Rather, the cells pile up into multicellular nodules and grow to very high saturation densities in plastic tissue culture dishes. Agents such as protein farnesyl transferase inhibitors which revert the *ras* transformed phenotype restore the uniform monolayer growth pattern to cells in culture. This reversion is easily monitored by counting the number of cells in tissue culture plates. Transformed cells will achieve higher cell numbers than cells which have reverted to an untransformed phenotype. Compounds which revert the transformed phenotype should produce antitumor effects in tumors bearing *ras* gene mutations.

Method:

Compounds are screened in tissue culture in NIH 3T3 cells transformed by the T24 activated human H-*ras* gene. Cells are seeded at an initial density of 200,000 cells per well (9.6 cm² surface area) in six-well cluster tissue culture plates. Test compounds are immediately added to 3.0 ml cell growth medium in a 3.0 µl volume of DMSO, with a final concentration of DMSO in the cell growth medium of 0.1%. The test compounds are run at concentrations of 5, 10, 50, 100, and 500 nM along with a DMSO treated vehicle control. (In case a high activity is observed at 5 nM, the test compound is tested at even lower concentrations.) The cells are allowed to proliferate for 72 hours. Then the cells are detached in 1.0 ml trypsin-EDTA cell dissociation medium and counted on a Coulter particle counter.

Measurements:


Cell numbers expressed as cells per well are measured using a Coulter Particle Counter. All cell counts were corrected for the initial cell input density by subtracting 200,000. Control cell counts = [cell counts from cells incubated with DMSO vehicle - 200,000] Test compound cell counts = [cell counts from cells incubated with test compound - 200,000].

Test compound %inhibition = $\left[1 - \frac{\text{test compound cell counts}}{\text{control cell counts}} \right] \times 100\%$.

Compounds 5, 7, 14 and 15 had an IC₅₀ less than 500 nM.

Claims

1. A compound of formula (I)



5

a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof, wherein

the dotted line represents an optional bond;

10 X is oxygen or sulfur;

R¹ and R² each independently are hydrogen, hydroxy, halo, cyano, C₁-6alkyl, trihalomethyl, trihalomethoxy, C₂-6alkenyl, C₁-6alkyloxy, hydroxyC₁-6alkyloxy, C₁-6alkyloxyC₁-6alkyloxy, C₁-6alkyloxycarbonyl, aminoC₁-6alkyloxy, mono- or di(C₁-6alkyl)aminoC₁-6alkyloxy, Ar¹, Ar¹C₁-6alkyl, Ar¹oxy or Ar¹C₁-6alkyloxy;

15 R³ and R⁴ each independently are hydrogen, halo, cyano, C₁-6alkyl, C₁-6alkyloxy, Ar¹oxy, C₁-6alkylthio, di(C₁-6alkyl)amino, trihalomethyl or trihalomethoxy;

R⁵ is hydrogen, halo, C₁-6alkyl, cyano, haloC₁-6alkyl, hydroxyC₁-6alkyl, cyanoC₁-6alkyl, aminoC₁-6alkyl, C₁-6alkyloxyC₁-6alkyl, C₁-6alkylthioC₁-6alkyl, aminocarbonylC₁-6alkyl, C₁-6alkyloxycarbonylC₁-6alkyl,

20 C₁-6alkylcarbonylC₁-6alkyl, C₁-6alkyloxycarbonyl, mono- or di(C₁-6alkyl)aminoC₁-6alkyl, Ar¹, Ar¹C₁-6alkyloxyC₁-6alkyl; or a radical of formula

-O-R¹⁰ (a-1),

-S-R¹⁰ (a-2),

25 -N-R¹¹R¹² (a-3),

wherein R¹⁰ is hydrogen, C₁-6alkyl, C₁-6alkylcarbonyl, Ar¹, Ar¹C₁-6alkyl, C₁-6alkyloxycarbonylC₁-6alkyl, or a radical of formula -Alk-OR¹³ or -Alk-NR¹⁴R¹⁵;

R¹¹ is hydrogen, C₁-6alkyl, Ar¹ or Ar¹C₁-6alkyl;

30 R¹² is hydrogen, C₁-6alkyl, C₁-6alkylcarbonyl, C₁-6alkyloxycarbonyl, C₁-6alkylaminocarbonyl, Ar¹, Ar¹C₁-6alkyl, C₁-6alkylcarbonyl-

5 C₁-6alkyl, Ar¹carbonyl, Ar¹C₁-6alkylcarbonyl, aminocarbonylcarbonyl, C₁-6alkyloxyC₁-6alkylcarbonyl, hydroxy, C₁-6alkyloxy, aminocarbonyl, di(C₁-6alkyl)aminoC₁-6alkylcarbonyl, amino, C₁-6alkylamino, C₁-6alkylcarbonylamino, or a radical or formula -Alk-OR¹³ or -Alk-NR¹⁴R¹⁵;



wherein Alk is C₁-6alkanediyl;

R¹³ is hydrogen, C₁-6alkyl, C₁-6alkylcarbonyl, hydroxyC₁-6alkyl, Ar¹ or Ar¹C₁-6alkyl;

R¹⁴ is hydrogen, C₁-6alkyl, Ar¹ or Ar¹C₁-6alkyl;

10 R¹⁵ is hydrogen, C₁-6alkyl, C₁-6alkylcarbonyl, Ar¹ or Ar¹C₁-6alkyl;

R⁶ is a radical of formula



15 wherein R¹⁶ is hydrogen, halo, Ar¹, C₁-6alkyl, hydroxyC₁-6alkyl, C₁-6alkyloxyC₁-6alkyl, C₁-6alkyloxy, C₁-6alkylthio, amino, C₁-6alkyloxycarbonyl, C₁-6alkylthioC₁-6alkyl, C₁-6alkylS(O)C₁-6alkyl or C₁-6alkylS(O)₂C₁-6alkyl;



R¹⁷ is hydrogen, C₁-6alkyl or di(C₁-4alkyl)aminosulfonyl;

20 R⁷ is hydrogen or C₁-6alkyl provided that the dotted line does not represent a bond;

R⁸ is hydrogen, C₁-6alkyl or Ar²CH₂ or Het¹CH₂;

R⁹ is hydrogen, C₁-6alkyl, C₁-6alkyloxy or halo; or

R⁸ and R⁹ taken together to form a bivalent radical of formula




Ar¹ is phenyl; or phenyl substituted with 1 or 2 substituents each independently selected from halo, C₁-6alkyl, C₁-6alkyloxy or trifluoromethyl;

30 Ar² is phenyl; or phenyl substituted with 1 or 2 substituents each independently selected from halo, C₁-6alkyl, C₁-6alkyloxy or trifluoromethyl; and

Het¹ is pyridinyl; pyridinyl substituted with 1 or 2 substituents each independently selected from halo, C₁-6alkyl, C₁-6alkyloxy or trifluoromethyl.

2. A compound according to claim 1 wherein R^1 and R^2 are each independently selected from hydrogen, halo or C_{1-4} alkyl; R^3 and R^4 are each independently selected from hydrogen, halo or C_{1-4} alkyl; R^5 is hydrogen, hydroxy, halo or a amino; R^6 is a radical of formula (b-1) or (b-2) wherein R^{16} is hydrogen or C_{1-4} alkyl and R^{17} is C_{1-4} alkyl; R^7 is hydrogen or C_{1-4} alkyl in case the dotted line does not represent a bond; R^8 is hydrogen; C_{1-4} alkyl or Het^1CH_2 ; and R^9 is hydrogen.
3. A compound according to any of claims 1 to 3 wherein X is oxygen, R^1 is 3-chloro, R^2 is hydrogen, R^3 is 4-chloro, R^4 is hydrogen, R^5 is hydrogen, C_{1-2} alkyl, halo or amino; R^6 is a radical of formula (b-1) or (b-2) wherein R^{16} is hydrogen and R^{17} is C_{1-2} alkyl; and R^7 is hydrogen or C_{1-2} alkyl in case the dotted line does not represent a bond; R^8 is hydrogen; C_{1-2} alkyl or Het^1CH_2 ; and R^9 is hydrogen.
4. A compound according to claim 1 wherein the compound is
6-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinazolinone; or
6-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-3,4-dihydro-1,3-dimethyl-2(1*H*)-quinazolinone; a stereoisomeric form or a pharmaceutically acceptable acid addition salt thereof.
5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as described in any one of claims 1 to 4.
6. A process for preparing a pharmaceutical composition as claimed in claim 5 wherein a therapeutically active amount of a compound as claimed in any one of claims 1 to 4 is intimately mixed with a pharmaceutically acceptable carrier.
7. A compound of formula (XI)




an acid addition salt or a stereochemically isomeric form thereof, wherein n is 2 or 3 and R^1 , R^2 , R^3 , R^4 and R^9 are as defined in claim 1.


5 8. A compound according to any one of claims 1 to 4 for use as a medicine.

9. A process for preparing a compound of formula (I) wherein

10 a) an intermediate of formula (III) is *N*-alkylated with an intermediate of formula (II) in a reaction-inert solvent and, optionally in the presence of a suitable base, yielding a compound of formula (I-a);




15 b) an intermediate of formula (IV) is reacted with a compound of formula (V), yielding a compound of formula (I-a);



20 c) an intermediate ketone of formula (VI) is reacted with an intermediate of formula (III-1) or (III-2) in the presence of a suitable strong base and in the presence an appropriate silanederivative, optionally followed by removal of a protective group PG; yielding either a compound of formula (I-b-1) or (I-b-2);

-33-



wherein in the above reaction schemes the dotted line and the radicals $X, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9$ and R^{16} are as defined in claim 1 and W is an appropriate leaving group;


5

d) or, compounds of formula (I) are converted into each other following art-known transformation reactions; or if desired; a compound of formula (I) is converted into a pharmaceutically acceptable acid addition salt, or conversely, an acid addition salt of a compound of formula (I) is converted into a free base form with alkali; and, if desired, preparing stereochemically isomeric forms thereof.

10

10. A process for preparing a compound of formula (XI) as claimed in claim 7 wherein an intermediate of formula (X) is cyclized in the presence of an ammonium salt and an appropriate base;

15



wherein in the above reaction scheme n is 2 or 3 and R^1 , R^2 , R^3 , R^4 and R^9 are as defined in claim 1;

- 5 or, compounds of formula (XI) are converted into each other following art-known transformation reactions; or if desired; a compound of formula (XI) is converted into a pharmaceutically acceptable acid addition salt, or conversely, an acid addition salt of a compound of formula (XI) is converted into a free base form with alkali;
10 and, if desired, preparing stereochemically isomeric forms thereof.

INTERNATIONAL SEARCH REPORT

1st Application No

PCT/EP 98/02357

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D403/06 C07D405/04 A61K31/505 C07D401/14
 //(C07D403/06,239:00,233:00)

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 664 128 A (SUMITOMO PHARMA) 26 July 1995 see examples 1-32	1,5,7,8
A	EP 0 371 564 A (JANSSEN PHARMACEUTICA NV) 6 June 1990 cited in the application see tables 7-B,9-B,10-B	1,5,7,8
A	WO 96 15118 A (ZENECA LTD ;BROWN DEARG SUTHERLAND (GB); MORRIS JEFFREY JAMES (GB)) 23 May 1996 see abstract	1,5,7,8

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

9 September 1998

Date of mailing of the international search report

16/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/02357

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
EP 0664128	A	26-07-1995	US	5646154 A	08-07-1997
			WO	9407498 A	14-04-1994
			JP	6192099 A	12-07-1994

EP 0371564	A	06-06-1990	AT	124941 T	15-07-1995
			AU	620946 B	27-02-1992
			AU	4564689 A	07-06-1990
			CA	2002864 A	29-05-1990
			CN	1042912 A,B	13-06-1990
			CN	1106004 A,B	02-08-1995
			CN	1106005 A,B	02-08-1995
			CY	1920 A	07-03-1997
			DE	68923430 D	17-08-1995
			DK	599489 A	30-05-1990
			ES	2088889 T	01-10-1996
			GR	3017351 T	31-12-1995
			HK	118196 A	12-07-1996
			HU	9500329 A	30-10-1995
			IE	67803 B	01-05-1996
			JP	2223579 A	05-09-1990
			NO	174509 B	07-02-1994
			PT	92448 A,B	31-05-1990
			SU	1780536 A	07-12-1992
			US	5037829 A	06-08-1991
			US	5441954 A	15-08-1995
			US	5612354 A	18-03-1997
			US	5185346 A	09-02-1993
			US	5268380 A	07-12-1993
			US	5028606 A	02-07-1991
			US	5151421 A	29-09-1992

WO 9615118	A	23-05-1996	AU	3813095 A	06-06-1996
			CA	2200871 A	23-05-1996
			EP	0790986 A	27-08-1997
			FI	971970 A	07-05-1997
			NO	972152 A	12-05-1997
			ZA	9509572 A	13-05-1996
